Objective: To identify the prevalence of glomerular filtration rate (GFR) less than 60 mL/min/1.73 m2 in Brazil and the associated factors.
Methods: This is a cross-sectional household-based epidemiological survey. Data were collected from the National Health Survey (PNS), conducted in 2013, by carrying out creatinine blood test and GFR calculation (n = 7,457). The groups of explanatory variables were: sociodemographic characteristics, lifestyles, chronic diseases, anthropometry, and health assessment. The prevalence of GFR < 60 mL/min/1.73 m2 and the respective 95% confidence intervals were estimated using the Poisson regression to calculate the crude and adjusted prevalence ratio (PR and adjPR) by age, sex, education level, and region.
Results: The prevalence of GFR < 60 mL/min/1.73 m2 was 6.48% (95%CI 5.88 - 7.09). After the adjustment, the following aspects remained associated: women (PR = 1.40; 95%CI 1.16 - 1.68), age of 45-59 years (adjPR = 7.27; 95%CI 3.8 - 14.1), 60 years or older (adjPR = 33.55; 95%CI 17.8 - 63.4), obesity (PR = 1.32 (95%CI 1.1 - 1.7), diabetes (PR = 1.44; 95%CI 1.2 - 1.8), poor/very poor self-rated health (PR = 1.50; 95%CI 1.2 - 1.9); and the lowest adjPR was found for the Northeast and Southeast regions, among smokers with high salt intake.
Conclusion: GFR < 60 mL/min/1.73 m2 was higher in women, increased with age, in addition to being associated with obesity, diabetes, and poor self-rated health. Knowing the prevalence of chronic kidney disease through biochemical tests and risk and protective factors are paramount to support public health policies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/1980-549720200101 | DOI Listing |
J Rheum Dis
January 2022
Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Objective: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role of renal function as a predictor of renal response.
Methods: From 2016 to 2019, we retrospectively reviewed 22 patients with refractory/relapsing LN receiving rituximab Renal responses (complete and partial) at 6 and 12 months were compared between normal (glomerular filtration rate [GFR]≥90 mL/min/173 m, n=11) and decreased (GFR<90 mL/min/173 m, n=11) GFR groups Multivariate Cox regression analysis was used to assess predictors of renal response.
Results: At baseline, the decreased GFR group had a higher urine proteinuria to creatinine ratio (p=0008) and proportion of refractory LN (p=0010) and previous cyclophosphamide therapy (p=0035) than the normal GFR group The overall renal response rate was 455% (10 patients) at 6 months and 545% (12 patients) at 12 months Renal response rates were higher in the normal GFR group (818% and 909% at 6 and 12 months, respectively) than in the decreased GFR group (91% and 182% at 6 and 12 months, respectively; p<0001) Normal GFR and anti-La were associated with renal response to rituximab, with hazard ratios of 9256 (p=0008) and 5478 (p=0041), respectively.
Int J Clin Pharmacol Ther
February 2004
Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Objectives: To compare the accuracy of the classification of the degree of decrease in glomerular filtration rate (GFR), measured exactly (as inulin clearance) on the basis of serum concentrations of creatinine (Scr), cystatin C (Scyst) and creatinine clearance predicted according to Cockcroft and Gault (CG), and to establish whether any of the above methods is more accurate than the other 2.
Subjects: The study was conducted in 126 patients (52 men, 74 women) aged 18 to 64 years with various chronic renal diseases (predominantly various forms of glomerulonephritis and tubulointerstitial nephritis). The study subjects were divided into 3 subgroups according to GFR levels.
Transplantation
October 1993
Department of Surgery, UCLA.
In this randomized controlled trial comparing FK-506 to CsA, we report parameters of nephrotoxicity in adult patients surviving > 90 days after orthotopic liver transplant (OLT). Patients randomized to FK-506 first received 0.15 mg/kg IV/day followed by 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!